A PHASE 3 RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, MULTICENTER STUDY OF THE ANALGESIC EFFICACY AND SAFETY OF A DOSE TITRATION REGIMEN FOR THE SUBCUTANEOUS ADMINISTRATION OF TANEZUMAB IN SUBJECTS WITH OSTEOARTHRITIS OF THE HIP OR KNEE

The primary purpose of this study is to evaluate the efficacy of a titration arm of tanezumab
in which treatment is started at a lower dose (2.5 mg) and increased to a higher dose (5 mg)
at Week 8, compared to giving 2 doses of tanezumab 2.5 mg or 2 doses of placebo. The study
also evaluates the safety of the treatment regimens.